Company: RGNX
Filing Date: 2025-03-13
Form Type: 10-K
Source: 0000950170-25-038770
Chunk: 208

Company: REGENXBIO Inc.
Filing Date: 2025-03-13
Form: 10-K
Item: Item 1B
Chunk 208
---
,679
    )

    468

    7,076

    Total operating expenses

    316,674

    358,370

    375,600

    (41,696
    )

    (17,230
    )

    Loss from operations

    (233,346
    )

    (268,128
    )

    (262,876
    )

    34,782

    (5,252
    )

    Other Income (Expense)

    Interest income from licensing

    174

    25

    342

    149

    (317
    )

    Investment income

    18,729

    11,319

    5,383

    7,410

    5,936

    Interest expense

    (12,659
    )

    (6,862
    )

    (23,254
    )

    (5,797
    )

    16,392

    Total other income (expense)

    6,244

    4,482

    (17,529
    )

    1,762

    22,011

    Loss before income taxes

    (227,102
    )

    (263,646
    )

    (280,405
    )

    36,544

    16,759

    Income Tax Benefit

    —

    152

    84

    (152
    )

    68

    Net loss
     
    $
    (227,102
    )
     
    $
    (263,494
    )
     
    $
    (280,321
    )
     
    $
    36,392

    $
    16,827

Comparison of the Years Ended December 31, 2024 and 2023

License and Royalty Revenue. License and royalty revenue decreased by $6.9 million, from $90.2 million for the year ended December 31, 2023 to $83.3 million for the year ended December 31, 2024. The decrease was primarily attributable to non-recurring development milestone revenue recognized in 2023, and Zolgensma royalty revenues, which decreased from $85.3 million in 2023 to $81.5 million in 2024. As reported by Novartis, sales of Zolgensma in 2024 were $1.21